Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

ABSTRACT:

Purpose

Clinicopathologic features and biochemical recurrence are sensitive, but not specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a genomic expression signature detected in the primary tumor represents true biological potential of aggressive disease and provides improved prediction of early prostate cancer metastasis.

Methods

A nested case-control design was used to select 639 patients from the Mayo Clinic tumor registry who underwent radical prostatectomy between 1987 and 2001. A genomic classifier (GC) was developed by modeling differential RNA expression using 1.4 million feature high-density expression arrays of men enriched for rising PSA after prostatectomy, including 213 who experienced early clinical metastasis after bioc

SUBMITTER: Erho N 

PROVIDER: S-EPMC3691249 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature